Nachrichten zur TG Therapeutics Inc. Aktie

TG Therapeutics (TGTX) Reports Q2 Loss, Tops Revenue Estimates

TG Therapeutics (TGTX) delivered earnings and revenue surprises of -30.77% and 15.75%, respectively, for the quarter ended June 2023. Do…

TG Therapeutics plunges after Q2 miss

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

TG Therapeutics Provides Business Update and Reports Second Quarter 2023 Financial Results

Second quarter 2023 BRIUMVI® net sales of $16 million in the United States, representing 100% quarter over quarter growth; total…

TG Therapeutics falls as Roche succeeds in Phase 3 trial for multiple sclerosis therapy

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

TG Therapeutics rises as Cantor sees strong Briumvi sales again

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Insiderhandel: Aufsichtsrat verkauft Aktien von TG Therapeutics im Wert von 814.538$

Lonial, Sagar - Aufsichtsrat - Tag der Transaktion: 2023-06-23...…

TG Therapeutics started at buy at Jefferies on MS asset Briumvi

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

TG Therapeutics to Participate in the 2023 Jefferies Healthcare Conference

Fireside chat scheduled for Wednesday, June 7, 2023, at 11:30 AM ET Fireside chat scheduled for Wednesday, June 7, 2023,…

TG Therapeutics Announces Presentation of Data from the ULTIMATE I & II Phase 3 Trials of BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the 2023 Consortium of Multiple Sclerosis Centers Annual Meeting

NEW YORK, June 02, 2023 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the presentation of data from…

TG Therapeutics granted EU nod for multiple sclerosis therapy Briumvi

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

TG Therapeutics Announces European Commission Approval for BRIUMVI® (ublituximab-xiiy) for the Treatment of Relapsing Forms of Multiple Sclerosis in Adults

NEW YORK, June 01, 2023 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that the European Commission (EC)…

TG Therapeutics Announces Data from the ULTIMATE I & II Phase 3 Trials of BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis to be Presented at the 2023 Consortium of Multiple Sclerosis Centers Annual Meeting

NEW YORK, May 31, 2023 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the details of an upcoming…

Why Apellis Pharmaceuticals, TG Therapeutics, and Viking Therapeutics Were on the Move Today

These three biotech stocks were on the volatile side today....…

TG Therapeutics Stock Jumps as 1Q Loss Narrows, Profit Surges

TG Therapeutics Stock Jumps as 1Q Loss Narrows, Profit Surges...…

TG Therapeutics (TGTX) Reports Q1 Loss, Tops Revenue Estimates

TG Therapeutics (TGTX) delivered earnings and revenue surprises of 22.22% and 105.94%, respectively, for the quarter ended March 2023. Do…

TG Therapeutics GAAP EPS of -$0.28 beats by $0.07, revenue of $7.8M beats by $4.42M

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

TG Therapeutics Provides Business Update and Reports First Quarter 2023 Financial Results

First quarter 2023 BRIUMVI net sales of $7.8 million...…

Form 8-K TG THERAPEUTICS, INC. For: May 01

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

TG Therapeutics to Host Conference Call on First Quarter 2023 Financial Results and Business Update

Conference call to be held Monday, May 1, 2023, at 8:30 AM ET Conference call to be held Monday, May…

TG Therapeutics gains after reimbursement win for multiple sclerosis therapy

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

TG Therapeutics Announces Issuance of Permanent J-Code for BRIUMVI® (ublituximab-xiiy) from Centers for Medicare and Medicaid Services

NEW YORK, April 27, 2023 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that the U.S.…

Why Shares of TG Therapeutics Soared on Tuesday

Early reports of strong sales for its recently approved multiple sclerosis drug gave the stock a jolt....…

TG Therapeutics jumps 22% as Cantor cites strong Briumvi sales

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

TG Therapeutics (TGTX) Stock Sinks As Market Gains: What You Should Know

TG Therapeutics (TGTX) closed at $15.48 in the latest trading session, marking a -1.46% move from the prior day....…

TG Therapeutics Gets CHMP Backing for Briumvi in Relapsing Multiple Sclerosis >TGTX

TG Therapeutics Gets CHMP Backing for Briumvi in Relapsing Multiple Sclerosis >TGTX...…

TG Therapeutics Announces Positive CHMP Opinion for BRIUMVI™ (ublituximab-xiiy) for the Treatment of Relapsing Forms of Multiple Sclerosis in Adults

NEW YORK, March 31, 2023 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that the Committee for Medicinal…

TG Therapeutics (TGTX) Stock Sinks As Market Gains: What You Should Know

TG Therapeutics (TGTX) closed the most recent trading day at $14.63, moving -1.48% from the previous trading session....…

TG Therapeutics (TGTX) Stock Sinks As Market Gains: What You Should Know

In the latest trading session, TG Therapeutics (TGTX) closed at $14.70, marking a -1.41% move from the previous day....…

TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of BRIUMVI™ (ublituximab-xiiy) in Multiple Sclerosis to be Presented at the American Academy of Neurology 75th Annual Meeting

NEW YORK, March 03, 2023 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of data presentations…

Form 10-K TG THERAPEUTICS, INC. For: Dec 31

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

TG Therapeutics (TGTX) Reports Q4 Loss, Tops Revenue Estimates

TG Therapeutics (TGTX) delivered earnings and revenue surprises of -50% and 100%, respectively, for the quarter ended December 2022. Do…

TG Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2022 Financial Results

Conference call to be held today, Tuesday, February 28, 2023, at 8:30 AM ET Conference call to be held today,…

TG Therapeutics to Host Conference Call on Fourth Quarter and Year-End 2022 Financial Results and Business Update

Conference call to be held Tuesday, February 28, 2023 at 8:30 AM ET Conference call to be held Tuesday, February…

TG Therapeutics Announces Presentation of Data from the ULTIMATE I & II Phase 3 Trials of BRIUMVI™ (ublituximab-xiiy) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum

NEW YORK, Feb. 24, 2023 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced presentations highlighting data from the…

TG Therapeutics (TGTX) Outpaces Stock Market Gains: What You Should Know

TG Therapeutics (TGTX) closed at $19.34 in the latest trading session, marking a +1.79% move from the prior day....…

TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of BRIUMVI™ (ublituximab) in Multiple Sclerosis to be Presented at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum

NEW YORK, Feb. 14, 2023 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of data presentations…

TG Therapeutics (TGTX) Stock Moves -0.89%: What You Should Know

In the latest trading session, TG Therapeutics (TGTX) closed at $14.50, marking a -0.89% move from the previous day....…

TG Therapeutics launches newly approved multiple sclerosis therapy

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

TG Therapeutics Announces Commercial Launch of BRIUMVI™ (ublituximab-xiiy) for the Treatment of Adult Patients with Relapsing Forms of Multiple Sclerosis

NEW YORK, Jan. 26, 2023 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced the commercial launch…

dpa-AFX ProFeed